Wearable devices detect CRS earlier after CAR T-cell therapy

Wearable devices accelerated detection of a common and potentially life-threatening complication among patients with multiple myeloma who underwent chimeric antigen receptor T-cell therapy, according to results of a pilot study.
The technology identified signs of cytokine release syndrome several hours earlier than standard hospital monitoring.
Validation of the findings in larger cohorts could support broader adoption of outpatient CAR T-cell therapy by eliminating the need for some recipients to have extended hospital stays, thereby reducing health care utilization while expanding access.






